Current Edition

Alnylam Pharmaceuticals

Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up

Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting …

Continue Reading →